Copyright
©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Oct 10, 2017; 8(5): 389-397
Published online Oct 10, 2017. doi: 10.5306/wjco.v8.i5.389
Published online Oct 10, 2017. doi: 10.5306/wjco.v8.i5.389
Stereotactic radiotherapy for prostate cancer: A review and future directions
Yusef A Syed, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30342, United States
Ami K Patel-Yadav, Charlotte Rivers, Department of Radiation Oncology, University at Buffalo, Buffalo, NY 14263, United States
Anurag K Singh, Department of Radiation Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, United States
Author contributions: Syed YA drafted the manuscript and compiled the tables; Patel-Yadav AK contributed technical oversight and edited the manuscript; Rivers C assisted in editing the manuscript; Singh AK developed the concept and led the editing process.
Conflict-of-interest statement: There are no conflicts of interest for any of the above listed authors.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Anurag K Singh, Professor, Department of Radiation Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, United States. anurag.singh@roswellpark.org
Telephone: +1-716-8451180 Fax: +1-716-8457616
Received: February 20, 2017
Peer-review started: February 23, 2017
First decision: June 14, 2017
Revised: July 12, 2017
Accepted: August 15, 2017
Article in press: August 16, 2017
Published online: October 10, 2017
Peer-review started: February 23, 2017
First decision: June 14, 2017
Revised: July 12, 2017
Accepted: August 15, 2017
Article in press: August 16, 2017
Published online: October 10, 2017
Core Tip
Core tip: Initial studies examining the use of stereotactic body radiotherapy (SBRT) in the treatment of prostate cancer have demonstrated impressive rates of biochemical recurrence-free survival and prostate specific antigen response, while maintaining a relatively favorable acute toxicity profile. Here we review a number of recent prospective and retrospective studies to evaluate the efficacy and toxicity of SBRT in the treatment of low, intermediate, and high-grade prostate cancer.